Emergo Therapeutics, Inc.
๐บ๐ธUnited States
- Country
- ๐บ๐ธUnited States
- Ownership
- Holding
- Established
- 2017-01-01
- Employees
- 11
- Market Cap
- -
Efficacy and Safety of Norketotifen in Uncomplicated Influenza-like Illness
Phase 2
Completed
- Conditions
- InfluenzaInfluenza -Like Illness
- Interventions
- Drug: Placebo
- First Posted Date
- 2020-10-30
- Last Posted Date
- 2023-01-30
- Lead Sponsor
- Emergo Therapeutics, Inc.
- Target Recruit Count
- 315
- Registration Number
- NCT04610047
- Locations
- ๐บ๐ธ
Clinovacare Medical Research Center, West Columbia, South Carolina, United States
๐บ๐ธHorizon Research Group of Opelousas, Eunice, Louisiana, United States
๐บ๐ธContinental Clinical Solutions, Towson, Maryland, United States
Norketotifen for the Treatment of Uncomplicated Influenza-like Illness
- First Posted Date
- 2019-08-02
- Last Posted Date
- 2021-03-24
- Lead Sponsor
- Emergo Therapeutics, Inc.
- Target Recruit Count
- 238
- Registration Number
- NCT04043923
- Locations
- ๐บ๐ธ
Family Medicine Associates of Texas, Carrollton, Texas, United States
๐บ๐ธCahaba Research, Birmingham, Alabama, United States
๐บ๐ธEmpire Clinical Research, Pomona, California, United States
Efficacy and Safety of Norketotifen in Adults With Allergic Rhinitis
Phase 2
Completed
- Conditions
- Allergic RhinitisAllergic Rhinoconjunctivitis
- Interventions
- Drug: Placebo
- First Posted Date
- 2019-03-22
- Last Posted Date
- 2020-08-21
- Lead Sponsor
- Emergo Therapeutics, Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT03887026
- Locations
- ๐บ๐ธ
Biogenics Research Chamber, San Antonio, Texas, United States
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Norketotifen in Healthy Subjects
Phase 1
Completed
- Conditions
- Healthy Subjects
- Interventions
- Drug: Norketotifen Oral Capsule (Cohort 3)Drug: Norketotifen Oral Capsule (Multiple Dose Cohort)Drug: Norketotifen Oral Capsule (Cohort 1)Drug: Norketotifen Oral Capsule (Cohort 2)Drug: Placebo Oral Capsule
- First Posted Date
- 2018-10-19
- Last Posted Date
- 2019-03-21
- Lead Sponsor
- Emergo Therapeutics, Inc.
- Target Recruit Count
- 74
- Registration Number
- NCT03712163
- Locations
- ๐บ๐ธ
Worldwide Clinical Trials, San Antonio, Texas, United States
ยฉ Copyright 2025. All Rights Reserved by MedPath